dr. flaherty on the rationale to explore triplet therapy in braf v600e-mutant melanoma
Published 5 years ago • 96 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
1:11
dr. flaherty on resistance in braf-mutant melanoma
-
2:26
dr. flaherty on the columbus trial updates in melanoma
-
6:01
beacon trial: triplet therapy in braf v600e–mutated mcrc
-
1:51
dr. flaherty discusses the columbus trial in melanoma
-
1:42
dr. flaherty on second-line therapy for braf-mutant melanoma
-
1:57
dr. flaherty discusses braf inhibitors in melanoma
-
1:02
dr. flaherty on the tolerability of encorafenib/binimetinib in melanoma
-
2:30
dr. keith t. flaherty on the nemo trial in nras-mutant melanoma
-
6:33
treatment of braf-mutant metastatic melanoma
-
2:11
dr. keith t. flaherty on 3-year follow-up of combi-d in metastatic melanoma
-
6:08
braf-mutant melanoma: frontline decisions
-
2:06
dr. polsky on the predictive value of ctdna in braf-mutant melanoma
-
6:08
braf-mutant melanoma: frontline decisions
-
10:08
emerging approaches for braf-mutant metastatic melanoma
-
6:12
braf as a driver in melanoma
-
6:03
mutations of clinical significance in melanoma
-
1:26
dr. nathan on long-term outcomes with dabrafenib/trametinib in braf v600-mutant melanoma
-
5:31
treating braf-mutated metastatic melanoma
-
4:44
novel approaches in melanoma